KR950017928A - 아세트산 유도체 - Google Patents

아세트산 유도체 Download PDF

Info

Publication number
KR950017928A
KR950017928A KR1019940032546A KR19940032546A KR950017928A KR 950017928 A KR950017928 A KR 950017928A KR 1019940032546 A KR1019940032546 A KR 1019940032546A KR 19940032546 A KR19940032546 A KR 19940032546A KR 950017928 A KR950017928 A KR 950017928A
Authority
KR
South Korea
Prior art keywords
lower alkyl
group
hydrogen
alkoxy
alkyl
Prior art date
Application number
KR1019940032546A
Other languages
English (en)
Other versions
KR100335541B1 (ko
Inventor
알리히 레오
하드바리 파울
휘르젤러 뮐러 마리안네
뮐러 마르셀
스타이너 베아트
벨러 토마스
Original Assignee
프리돌린 클라우스너, 롤란드 보러
에프. 호프만-라 롯슈 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리돌린 클라우스너, 롤란드 보러, 에프. 호프만-라 롯슈 아크티엔게젤샤프트 filed Critical 프리돌린 클라우스너, 롤란드 보러
Publication of KR950017928A publication Critical patent/KR950017928A/ko
Application granted granted Critical
Publication of KR100335541B1 publication Critical patent/KR100335541B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/16Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • C07C323/42Y being a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/04Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/071,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2479Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1)
    • C07F9/2491Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1) containing the structure P(=X)n-N-N (X = O, S, Se; n = 0, 1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

하기 일반식( I )의 아세트산 유도체는 혈소판에 유착성 단백질의 결합 및 혈소판 응집 및 세포-세포 유착에 의해 야기된 질병의 치료 또는 예방에 유용할 수 있다. 이들은 상응하는 보호된 화합물의 보호 그룹을 분리하거나 또는 사용하는 니트릴에서 시아노 그룹을 아미디노 그룹으로 전환시키므로써 제조할 수 있다.
(상기식에서, L, M, T 및 Q는 명세서에 개시한 바와 같은 의미를 갖는다.

Description

아세트산 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. 하기 일반식( I )의 아세트산 유도체, 그의 수화물 또는 용매화물 및 생리학적으로 유용한 그의 염;
    I
    상기식에서, L은 하기 일반식 L1내지 L5의 그룹이고,
    L1
    L2
    L3
    L4
    L5
    이때, L그룹 및/또는 아미드 형태로 결합되지 않은 L과 M그룹사이에 존재하는 카보닐 그룹은 또한 옥심으로 존재할 수 있고, A는 하기 일반식 A1내지 A4의 그룹이고;
    A1
    A2
    A3
    A4
    [이때, E1및 E2는 수소, 저급 알킬, 하이드록시, 저급 알콕시, 저급 알콕시-저급 알킬, 카복시-저급알킬, p(O)(O-저급 알킬)2,C(O)OR1, OC(O)R1, OC(O)OR1또는 C(O)SR1이나, 단 E1및 E2중 적어도 하나는 수소이거나, 또는 E1및 E2는 이들이 결합된 질소 원자와 함께 (5,5-디메틸 또는 5-옥소)-4,5-디하이드로-1,2,4-옥사디아졸-3-일 그룹을 형성하고, R1은 저급 알콕시-저급 알킬: 저급 알킬 OH, COOH, 저급 알콕시카보닐, 저급 알카노일옥시, 저급 알케노일옥시로 치환된 저급 알킬, 임의 치환 도니 벤조일옥시로 치환된 저급 알킬 도는 저급 알길-CONH에 의해 치환된 저급 알킬: 또는 임의 치환되고 저급 알킬렌에 의해 임의 결합된 페닐; 또는 0에 의해 임의로 차단된 사이클로알킬이고, 이때 X 및 Y중 하나는 CH이고, 다른 하나는 CH, C-저급 알킬, C-저급 알콕시 또는 N이고, D는 (CH2)s또는 (CH2)1O 그룹이고, s는 1 내지 4이과, m 및 n은 0 내지 5이고, t는 0 내지 3이나, m+n은 1 내지 5이고, m+t 및 n+t는 각각 적어도 1이고, p 및 q는 0 내지 5이나, p+q는 2 내지 5이고, W1은 CH2,알킬-CH, 저급 알킬-OC(O)CH, NH, 저급 알킬-N 또는 저급 알콕시-저급 알킬-N이고, W2는 O, NH, 아실-N 또는 저급 알킬-OC(O)-N이고, G는 H 또는 α-아미노카복실산의 특징 부여 그룹이다] M은 N원자에 의해 케토 그룹에 결합된 1,4-피페리디닐렌; 또는 저급 알킬, 저급 알콕시, OCH2COOH 또는 OCH2COO 저급 알킬로 임의 치환된 1,4-페닐렌이고, Q는 O, CH2, NH, 아실-N 또는 저급 알킬 OC(0)N이고, T는 NH2, NH-저급 알킬, NH-저급 알킬(COOH 또는 COO-저급 알킬); 저급 알콕시 COOH, COO-저급 알킬, 저급 알킬-COO 또는 저급 알킬-OCOO에 의해 치환된 저급 알콕시 또는 저급 알케닐옥시; 또는 OT' 그룹이고, T'는 수소; 저급 알킬; 저급 알킬렌에 의해 임의 결합된 페닐 또는 피리딜: 또는 저급 알킬렌에 의해 임의 결합되고, O, NH 또는 NCOO-저급 알킬로 임의의 차단된 사이클로알킬이나, 단, a) L이 하기 일반식(L')의 그룹이고:
    (이때, A는 하기 일반식(A')의 그룹이고:
    E1및 E2중 하나는 수소이고, 다른 하나는 수소, 1-부톡시카보닐 또는 벤질옥시카보닐이고, X 및 Y 중 하나는 CH이고, 다른 하나는 CH 또는 N이고, W1은 NH, 저급 알킬-N 또는 저급 알콕시-저급 알킬 -N이고, G는 상기와 갈은 의미를 갖는다) M이 N원자에 의해 케토 그룹에 곁합된 1,4-피페리디닐렌이고, Q가 O인 경우, T'는 수소, 저급 알킬 및 페닐-저급 알킬이 아니고, b) L이 L11, L31또는 L41의 그룹이과 :
    (이때, A는 하기 일반식(A1)의 그룹이고,
    E1및 E2중 하나는 수소이고, 다른 하나는 수소, t-부톡시카보닐 또는 벤질옥시카보닐이고, X 및 Y중 하나는 CH이고, 다른 하나는 CH, C- 저급 알킬, C- 저급 알콕시 또는 N이고, R0및 G0는 수소 또는 저급 알킬이고, W4는 C=O 또는 C=NOH이다.) M이 저급 알킬, 저급 알콕시, OCH2COOHO 또는 CH2COOH- 저급 알킬로 임의 치환된 1,4-페닐렌이고, Q가 O, CH2, 또는 NH인 경우, T'는 수소, 저급 아킬, 페닐 및 페닐-저급 알킬이 아니다.
  2. 활성 물질로 제1항의 화합물을 함유하는, 혈소판에 유착성 단백질의 결합 및 혈소판 응집 및 세포-세포 유착에 의해 야기되는 질병의 치료 또는 예방에 유용한 약제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940032546A 1993-12-03 1994-12-02 아세트산유도체 KR100335541B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH3609/93 1993-12-03
CH3609.93 1993-12-03
CH360993 1993-12-03
CH319894 1994-10-25
CH3198/94 1994-10-25

Publications (2)

Publication Number Publication Date
KR950017928A true KR950017928A (ko) 1995-07-20
KR100335541B1 KR100335541B1 (ko) 2003-06-11

Family

ID=25692439

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940032546A KR100335541B1 (ko) 1993-12-03 1994-12-02 아세트산유도체

Country Status (29)

Country Link
US (2) US5726185A (ko)
EP (1) EP0656348B1 (ko)
JP (1) JP2901509B2 (ko)
KR (1) KR100335541B1 (ko)
CN (1) CN1075062C (ko)
AT (1) ATE192430T1 (ko)
AU (1) AU687905B2 (ko)
BG (1) BG62399B1 (ko)
CA (1) CA2136903C (ko)
CZ (1) CZ290024B6 (ko)
DE (1) DE59409322D1 (ko)
DK (1) DK0656348T3 (ko)
ES (1) ES2147210T3 (ko)
FI (2) FI945688A (ko)
GR (1) GR3034111T3 (ko)
HU (1) HUT71332A (ko)
IL (1) IL111784A0 (ko)
IS (1) IS4237A (ko)
LV (1) LV11318B (ko)
MY (1) MY112417A (ko)
NO (1) NO302169B1 (ko)
NZ (1) NZ270020A (ko)
PT (1) PT656348E (ko)
RO (1) RO117846B1 (ko)
RU (1) RU2151768C1 (ko)
SI (1) SI0656348T1 (ko)
SK (1) SK282058B6 (ko)
TW (1) TW472042B (ko)
UA (1) UA35592C2 (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2157345T3 (es) * 1994-10-07 2001-08-16 Meiji Seika Co Compuestos de gamma-dicetona con actividad inhibidora contra la agregacion de plaquetas.
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規2−アミノ−3−フェニルプロピオン酸誘導体
US6013651A (en) * 1995-08-30 2000-01-11 G. D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
ES2161373T3 (es) * 1995-08-30 2001-12-01 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
CA2250464A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
DE19622189A1 (de) * 1996-06-03 1997-12-04 Bayer Ag 3-Cyanaryl-pyrazole
JP2001512439A (ja) * 1997-02-06 2001-08-21 メルク エンド カンパニー インコーポレーテッド 線維素原受容体拮抗薬プロドラッグ
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
JP2002533416A (ja) 1998-12-23 2002-10-08 ジー.ディー.サール & カンパニー 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−2インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1677783A2 (en) 2003-10-08 2006-07-12 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc RELEASE OF LFA-1 ANTAGONISTS AGAINST THE GAS-DARM SYSTEM
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2011521896A (ja) * 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所lfa−1アンタゴニスト
EP2265124A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
PT2750677T (pt) 2011-08-30 2017-07-03 Chdi Foundation Inc Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
JP6607780B2 (ja) 2012-07-25 2019-11-20 サルコード・バイオサイエンス・インコーポレイテッド Lfa−1阻害剤およびその多形
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
UA120856C2 (uk) 2014-07-17 2020-02-25 Кхді Фаундейшн, Інк. Способи та композиції для лікування розладів, пов'язаних з віл
JPWO2020059812A1 (ja) 2018-09-20 2021-08-30 小野薬品工業株式会社 4−({(4s)−1−(4−カルバムイミドイルベンゾイル)−4−[4−(メチルスルホニル)ピペラジン−1−イル]−l−プロリル}アミノ)安息香酸の新規塩およびその新規結晶形
CN113075343B (zh) * 2020-01-04 2024-02-23 东莞市东阳光仿制药研发有限公司 一种羟胺及其盐的检测方法
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5256812A (en) * 1989-01-31 1993-10-26 Hoffmann-La Roche Inc. Carboxamides and sulfonamides
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
RU2097378C1 (ru) * 1991-03-26 1997-11-27 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ N-АЦИЛ- α -АМИНОКИСЛОТЫ ИЛИ ИХ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, ПРОСТЫЕ ИЛИ СЛОЖНЫЕ ЭФИРЫ, АМИДЫ ИЛИ ГИДРАТЫ И КОМПОЗИЦИЯ ИНГИБИРУЮЩАЯ СВЯЗЫВАНИЕ АДГЕЗИВНЫХ ПРОТЕИНОВ С ТРОМБОЦИТАМИ И АГРЕГАЦИЮ ТРОМБОЦИТОВ
DE4213919A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH08505391A (ja) * 1992-12-30 1996-06-11 スミスクライン・ビーチャム・コーポレイション 化合物
WO1994021599A1 (en) * 1993-03-17 1994-09-29 Meiji Seika Kabushiki Kaisha Novel compound with platelet aggregation inhibitor activity
GB9313269D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Allophanic acid derivatives
US5607948A (en) * 1993-06-30 1997-03-04 Sumitomo Pharmaceuticals Co., Ltd. Dipiperidine derivatives

Also Published As

Publication number Publication date
IS4237A (is) 1995-06-04
RO117846B1 (ro) 2002-08-30
NZ270020A (en) 1997-05-26
SK282058B6 (sk) 2001-10-08
US5726185A (en) 1998-03-10
ES2147210T3 (es) 2000-09-01
DK0656348T3 (da) 2000-09-11
PT656348E (pt) 2000-10-31
UA35592C2 (uk) 2001-04-16
EP0656348A3 (de) 1995-09-06
RU94042929A (ru) 1996-10-27
JP2901509B2 (ja) 1999-06-07
ATE192430T1 (de) 2000-05-15
CA2136903A1 (en) 1995-06-04
GR3034111T3 (en) 2000-11-30
BG99233A (en) 1995-09-29
EP0656348B1 (de) 2000-05-03
MY112417A (en) 2001-06-30
HUT71332A (en) 1995-11-28
LV11318A (lv) 1996-06-20
AU7909094A (en) 1995-06-08
CA2136903C (en) 2006-06-06
NO944650D0 (no) 1994-12-02
KR100335541B1 (ko) 2003-06-11
BG62399B1 (bg) 1999-10-29
NO302169B1 (no) 1998-02-02
RU2151768C1 (ru) 2000-06-27
EP0656348A2 (de) 1995-06-07
CN1112104A (zh) 1995-11-22
TW472042B (en) 2002-01-11
CZ290024B6 (cs) 2002-05-15
NO944650L (no) 1995-06-06
HU9403441D0 (en) 1995-02-28
JPH07196592A (ja) 1995-08-01
IL111784A0 (en) 1995-01-24
SK145894A3 (en) 1995-09-13
FI945688A (fi) 1995-06-04
FI945688A0 (fi) 1994-12-02
FI20011980A (fi) 2001-10-11
CZ301194A3 (en) 1995-09-13
CN1075062C (zh) 2001-11-21
US5973188A (en) 1999-10-26
AU687905B2 (en) 1998-03-05
LV11318B (en) 1996-10-20
DE59409322D1 (de) 2000-06-08
SI0656348T1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
KR950017928A (ko) 아세트산 유도체
AU688628B2 (en) Novel amidinonaphthyl derivative or salt thereof
AU659629B2 (en) N-acyl-alpha-amino acid derivatives
HU9300274D0 (en) Phosphonoxical as well as carbonatic derivatives of taxole and medical preparatives containing said active substance
WO2001009103A3 (en) Imidazole antiproliferative agents
KR900018098A (ko) 피리돈 카르복실산과 항균제
CA2281426A1 (en) Substituted indole compounds as anti-inflammatory and analgesic agents
EP0671390A3 (en) Antithrombotic agents
DK0659427T3 (da) 2-Phenyl-3-azoylbenzothiophener til forøgelse af thrombomodulinekspression
DE69315699D1 (de) Inhibitoren gegen die aggregation von blutplättchen
RU94039539A (ru) N,n'-замещенные имидокарбонимидные диамиды, получаемые из гидроксиламинов, имеющие антимикробную и антипаразитическую активность, профилактическая композиция, композиция для снижения уровня инфекций
AU6582394A (en) Novel bisoxadiazolidine derivative
AU2983792A (en) Diaminomethyleneamino substituted substituted phenyl thiazoles
ES8505662A1 (es) Procedimiento para la obtencion de oximeteres sustituidos por 1-azolilo
WO2002026708A1 (fr) Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif
PL338700A1 (en) Methods of reducing number of thrombocytes in blood
TW366283B (en) Compounds for treatment of arrhythmia
EP0372410A3 (en) Use of heterocyclic amides to inhibit tumor metastasis
YU49054B (sh) Derivati sirćetne kiseline, njihova primena, postupak za njihovo dobivanje i farmaceutski preparati koji sadrže ta jedinjenja
GB1384441A (en) Benzomorphan derivatives

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060331

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee